Bregni M, Siena S, Di Nicola M, Bonadonna G and Gianni AM: Tropisetron plus Haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy. 


Bregni M, Magni M, Siena S, Di Nicola M, Bonadonna G and Gianni AM:Human peripheral blood hematopoietic progenitors are optimal targets of retroviral mediated gene transfer. 

Gianni AM, Bregni M, Siena S, Magni M, Di Nicola M, Lombardi F, Tarella C, Pileri A and Bonadonna G:GM-CSF or G-CSF infusion makes high-dose Etoposide a safe outpatient regimen, that is effective in lymphoma and myeloma patients. 

Gianni AM, Siena S, Bregni M, Di Nicola M, Peccatori F, Magni M, Ravagnani F, Sklenar I and Bonadonna G: Recombinant human interleukin-3 hastens trilineage hematopoietic recovery following high-dose (7 g/m²) cyclophosphamide cancer therapy. 

Siena S, Bregni M, Bonsi L, Strippoli P, Peccatori F, Magni M, Di Nicola M, Bagnara G, Gianni AM:Clinical implications of the heterogeneity of hematopoietic progenitors elicited in peripheral blood by anticancer theraphy with cyclophosphamide and cytokine(s). 


Gianni AM, Siena S, Bregni M, Lombardi F, Gandola L, Di Nicola M, Magni M, Peccatori F, Valagussa P, and Bonadonna G: High dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin’s disease - a 6-year
update.

Ann Oncol 1993; 4: 889-891  
I.F.: 6.424   C.I.: 54

Ann Oncol 1994; 5: 935-941  

Bone Marrow Transpl 1994;14, 863-869  
I.F.: 3.746   C.I.: 6

Exp Hematol 1995; 23: 1463-1471  
I.F.: 2.905   C.I.: 216

J Clin Oncol 1996; 14: 628-635  
I.F.: 18.373   C.I.: 33

Tumori 1996; 2: 23-27  
I.F.: 0.606   C.I.: nd

Tissue Antigens 1996; 48: 65-68  
I.F.: 2.588   C.I.: 2

17 Di Nicola M, Bregni M, Siena S, Ruffini PA, Milanesi M, Ravagnani F, Gianni AM: Combined negative and positive selection of peripheral blood mobilized CD34+ cell transplants.
Brit J Haematol 1996; 94: 716-721  
I.F.: 4.941   C.I.: 17

18 Di Nicola M, Siena S, Bregni M, Belli N, Milanesi M, Ruffini PA, Malaffo F, Ravagnani F, Gianni AM: Benefits of blood cell transplant cryopreservation with oxypolygelatine (Gelifundol) plasma substitute.
Bone Marrow Transp 1996; 18: 619-623  
I.F.: 3.746   C.I.: 8

Bone Marrow Transp 1996; 18: 1117-1121  
I.F.: 3.746   C.I.: 25


24 Bregni M, Di Nicola M, Siena S, Belli N, Milanesi M, Shammah S, Ravagnani F, Gianni AM: Mobilized peripheral blood CD34+ cells express more amphotropic retrovirus receptor than bone marrow CD34+ cells.


Tumori 1998;84: 612-613 I.F.: 0.606 C.I.: 2


29 Di Nicola M, Longoni P, Magni M, Gianni AM: The influence of interleukin (IL)-4 and IL-13 on human dendritic cell differentiation from CD34+ progenitor cells: the importance of the source of serum.

30 Di Nicola M, Milanesi M, Magni M, Bregni M, Carlo-Stella C, Longoni P, Tomanin R,


*Equally contributed


38 Tarella C, Di Nicola M, Caracciolo D, Zallio F, Cittica A, Omedè P, Bondesan P, Magni M,


46 H.M.Bond, M.Mesuraca, E.Carbone, P.Bonelli, V.Agosti, N.Amodio, G.De Rosa, M.Di


I.F.: 2.905  C.I.: 20


I.F.: 4.941  C.I.: 15


I.F.: 7.742  C.I.: 45


I.F.: 9.898  C.I.: 8


I.F.: 7.856  C.I.: 23


I.F.: 6.424  C.I.: 12

malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice.

I.F.: 2.905  C.I.: 6

Hum Gene Ther 2006 Dec;17(12):1225-40
I.F.: 4.218  C.I.: 17

Haematologica 2006 Dec;91(12):1635-43

Stem Cells 2007 Jan;25:252-61
I.F.: 7.781  C.I.: 7

Blood 2007 Mar 15;109(6):2571-8
I.F.: 9.898  C.I.: 72

Cancer Res 2007 Apr 1;67(7):3269-75
I.F.: 7.856  C.I.: 6

I.F.: 9.561  C.I.: 29

I.F.: 2.905  C.I.: 2

I.F.: 6.424  C.I.: 10
Corresponding Author


marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.


Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.

75 Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E, Parmiani G; NIBIT.


* con Editoriale


EDITORIALS AND REVIEWS PUBLISHED PEER-REVIEWED JOURNALS


2. Di Nicola M, Bregni M, Siena S, Gianni AM: Fattori di crescita emopoietici in oncologia medica. in Progressi in Oncologia Medica 1993; 4, (suppl. 1), 147-163


*Front Immunol.* 2015 Sep 1;6:448
**BOOK CHAPTERS**

   

   
   in “Progressi in Ematologia clinica”, 13, 177-183, 1994

   

   

   

   

   
